VYNE Therapeutics
Stock Forecast, Prediction & Price Target
VYNE Therapeutics Financial Estimates
VYNE Therapeutics Revenue Estimates
VYNE Therapeutics EBITDA Estimates
VYNE Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $14.75M N/A | $477K -96.76% | $424K -11.11% | Avg: $250K Low: $235.29K High: $264.70K avg. -41.03% | Avg: $250K Low: $235.29K High: $264.70K avg. 0% | Avg: $10.25M Low: $9.64M High: $10.85M avg. 4000% | Avg: $13.6M Low: $12.8M High: $14.4M avg. 32.68% |
Net Income
% change YoY
| $-73.32M N/A | $-33.94M 53.70% | $-28.45M 16.18% | Avg: $-40.7M Low: $-8.73M High: $-7.49M avg. -43.04% | Avg: $-46.2M Low: $-7.74M High: $-6.64M avg. -13.51% | Avg: $-7.70M Low: $-8.29M High: $-7.11M avg. 83.32% | Avg: $-11.81M Low: $-12.71M High: $-10.91M avg. -53.33% |
EBITDA
% change YoY
| $-68.16M N/A | $-33.93M 50.22% | $-29.25M 13.77% | Avg: $-250K Low: $-264.70K High: $-235.29K avg. 99.14% | Avg: $-250K Low: $-264.70K High: $-235.29K avg. 0% | Avg: $-10.25M Low: $-10.85M High: $-9.64M avg. -4000% | Avg: $-13.6M Low: $-14.4M High: $-12.8M avg. -32.68% |
EPS
% change YoY
| -$25.65 N/A | -$10.65 58.47% | -$2.77 73.99% | Avg: -$0.79 Low: -$0.85 High: -$0.73 avg. 71.48% | Avg: -$0.7 Low: -$0.75 High: -$0.65 avg. 11.39% | Avg: -$0.75 Low: -$0.81 High: -$0.69 avg. -7.14% | Avg: -$1.15 Low: -$1.24 High: -$1.06 avg. -53.33% |
Operating Expenses
% change YoY
| $79.43M N/A | $34.77M -56.22% | $29.68M -14.63% | Avg: $6.23M Low: $5.86M High: $6.59M avg. -79.01% | Avg: $6.23M Low: $5.86M High: $6.59M avg. 0% | Avg: $255.43M Low: $240.41M High: $270.46M avg. 4000.00% | Avg: $338.92M Low: $318.98M High: $358.85M avg. 32.68% |
FAQ
What is VYNE Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -6.64% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -8.73M, average is -40.7M and high is -7.49M.
What is VYNE Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 997.91% in 2025-2028.
We have gathered data from 1 analysts. Their low revenue estimate is $235.29K, average is $250K and high is $264.70K.
What is VYNE Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 5.59% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$0.85, average is -$0.79 and high is $-0.72.
What is the best performing analyst?
In the last twelve months analysts have been covering VYNE Therapeutics stock. The most successful analyst is Joseph Pantginis.